Genscript Biotech Dirección
Dirección controles de criterios 1/4
El CEO de Genscript Biotech es Weihui Shao , nombrado en Jul 2021, tiene una permanencia de 3.33 años. compensación anual total es $2.48M, compuesta por 14.3% salario y 85.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.034% de las acciones de la empresa, por valor de HK$7.65M. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 1.7 años, respectivamente.
Información clave
Weihui Shao
Chief Executive Officer (CEO)
US$2.5m
Compensación total
| Porcentaje del salario del CEO | 14.3% |
| Permanencia del CEO | 3.3yrs |
| Participación del CEO | 0.03% |
| Permanencia media de la dirección | 3.6yrs |
| Promedio de permanencia en la Junta Directiva | 1.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)
Nov 19
Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Oct 01What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Sep 16After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar
Aug 02Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch
Jun 05A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)
May 10Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 13Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%
Mar 13Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jan 26Is Genscript Biotech (HKG:1548) A Risky Investment?
Nov 21Is Genscript Biotech (HKG:1548) A Risky Investment?
Aug 22Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook
Apr 04Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report
Apr 03Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 02Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate
Feb 07What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Dec 14Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate
Nov 09Is Genscript Biotech (HKG:1548) Using Debt Sensibly?
Oct 22Health Check: How Prudently Does Genscript Biotech (HKG:1548) Use Debt?
Apr 03Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?
Oct 03Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?
Sep 07Estimating The Fair Value Of Genscript Biotech Corporation (HKG:1548)
Aug 16Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?
Jun 03Is Genscript Biotech Corporation (HKG:1548) Trading At A 49% Discount?
May 13Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Apr 16Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?
Mar 20Are Insiders Selling Genscript Biotech Corporation (HKG:1548) Stock?
Feb 13
Did The Underlying Business Drive Genscript Biotech's (HKG:1548) Lovely 753% Share Price Gain?
Jan 09Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$177m |
| Mar 31 2024 | n/a | n/a | -US$136m |
| Dec 31 2023 | US$2m | US$353k | -US$95m |
Compensación vs. Mercado: La compensación total de Weihui($USD2.48M) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD481.50K).
Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Weihui con los resultados de la empresa.
CEO
Weihui Shao (44 yo)
3.3yrs
Permanencia
US$2,477,000
Compensación
Ms. Weihui Shao is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined the Genscript Biotech Co...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 9.3yrs | US$495.00k | 0.013% HK$ 3.0m | |
| CEO & COO | 3.3yrs | US$2.48m | 0.034% HK$ 7.7m | |
| Co-Founder | 22.8yrs | US$659.00k | 0.036% HK$ 8.3m | |
| Co-Founder & Non-Executive Director | no data | sin datos | 0.030% HK$ 6.8m | |
| Co-Founder & Executive Director | 1.9yrs | US$531.00k | sin datos | |
| Chief Strategy Officer & Executive Director | 4yrs | US$320.00k | 0.054% HK$ 12.2m | |
| Chief Financial Officer | 3.9yrs | sin datos | sin datos | |
| Chief Marketing Officer for GenScript Life Science Group | no data | sin datos | sin datos |
3.6yrs
Permanencia media
56yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de 1548 se considera experimentado (3.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 9.3yrs | US$495.00k | 0.013% HK$ 3.0m | |
| Co-Founder | 9.5yrs | US$659.00k | 0.036% HK$ 8.3m | |
| Co-Founder & Non-Executive Director | 9.5yrs | sin datos | 0.030% HK$ 6.8m | |
| Co-Founder & Executive Director | 2.5yrs | US$531.00k | sin datos | |
| Chief Strategy Officer & Executive Director | 4yrs | US$320.00k | 0.054% HK$ 12.2m | |
| Member of Advisory Board | less than a year | sin datos | sin datos | |
| Member of Advisory Board | 5.2yrs | sin datos | sin datos | |
| Independent Non-Executive Director | less than a year | sin datos | sin datos | |
| Member of Scientific Advisory Board | less than a year | sin datos | sin datos | |
| Independent Non-Executive Director | less than a year | sin datos | sin datos | |
| Independent Non-Executive Director | less than a year | sin datos | sin datos | |
| Independent Non-Executive Director | less than a year | sin datos | sin datos |
1.7yrs
Permanencia media
61.5yo
Promedio de edad
Junta con experiencia: La junta directiva de 1548 no se considera experimentada (1.7 años de permanencia promedio), lo que sugiere una nueva junta directiva.